Gamida Cell Ltd

Gamida Cell — Investor Day (December 2020)

66 slides from Gamida Cell's investor day presentation, Dec 9, 2020

  1. Slide 1: Inspired to Cure Pipeline Deep Dive

    1 Inspired to Cure Pipeline Deep Dive Julian Adams, Ph.D. CEO December 9, 2020

  2. Slide 2: Disclaimer

    2 Disclaimer This Presentation includes certain projections and forward - looking statements as of the date of this Presentation provided by Gamida Cell Ltd. (the “company”). The information in this Presentation is current only as of its date and may have changed since that date. These projections a

  3. Slide 3: Agenda

    3 Agenda • Gamida Cell introduction • Omidubicel overview and science of NAM • Omidubicel Phase 3 HSCT and Phase 2 Severe Aplastic Anemia clinical data • Bringing omidubicel to patients • GDA - 201: An innovation in NK cell therapy • An omidubicel patient’s perspective • Q&A 3

  4. Slide 4: We are pioneering new, potentially curative advanced cell therapies

    4 We are pioneering new, potentially curative advanced cell therapies.

  5. Slide 5: Pipeline and milestones

    5 CANDIDATE PRECLINICAL PHASE 1 PHASE 2 PHASE 3 MILESTONES OMIDUBICEL High - Risk Hematologic Malignanci e s x Topline data 2Q20 x Detailed data presentation 4Q20 □ BLA submission 4Q20 Severe Aplastic Anemia* x Additional data 4Q20 GDA - 201 Non - Hodgkin Lymphoma, Multiple Myeloma x Additional data

  6. Slide 6: Omidubicel: A Potentially Curative Treatment For Patients In Need Of A Bone Marrow Transplant

    Omidubicel 6 A Potentially Curative Treatment For Patients In Need Of A Bone Marrow Transplant Tracey Lodie, Ph.D. Chief Scientific Officer

  7. Slide 7: Mechanism of action: Nicotinamide (NAM) platform used to fight cancer

    Mechanism of action: Nicotinamide (NAM) platform used to fight cancer e d • Inhibits NAD - related signaling pathways • Attenuates genes/pathways involv in stress, reactive oxygen species production, and inflammation • Switches cell metabolism to anaerobic glycolysis during expansion • Preserves cel

  8. Slide 8: NAM technology: mechanism of action

    NAM technology: mechanism of action NAM leads to a preserved gene signature during ex vivo cell expansion which preserves stemness and increases in vivo engraftment NH 2 O N NAM Preserved Gene Expression Non - cultured Cultured w/o NAM Cultured +NAM Increased Engraftment Efficacy NAM cultured CD34 +

  9. Slide 9: NAM up-regulates key TFs responsible for stem cell renewal and DNA repair

    NAM up - regulates key TF’s responsible for stem cell renewal and DNA repair while down - regulating TF’s that activate cell differentiation, inflammation, and apoptosis Biological / Functional enrichment • HPC differentiation (mTOR, JNK, cMYC, NF - kB, cJUN) • Inflammatory signaling (IFNγ,TNFα, TLR

  10. Slide 10: Ex vivo expansion with NAM mimics the hypoxic conditions in the bone marrow niche

    10 Ex vivo expansion with NAM mimics the hypoxic conditions in the bone marrow niche Characteristics of the bone marrow niche that preserve HSCs function Quiescent environment Undifferentiated stem cells Low O , High ROS scavenging 2 Dense Extracellular Matrix Differentiation ROS secretion MMPs acti

  11. Slide 11: Omidubicel: A Potentially Curative Treatment For Patients In Need Of A Bone Marrow Transplant

    Omidubicel 11 A Potentially Curative Treatment For Patients In Need Of A Bone Marrow Transplant Ronit Simantov, M.D. Chief Medical Officer

  12. Slide 12: Bone marrow transplant may be curative for certain hematologic malignancies

    Bone marrow transplant may be curative for certain hematologic malignancies Patient diagnosed with hematologic malignancy Eligible for transplant Potentially cured patient T reatment Hematopoietic Stem Cell Transplant (HSCT) 12

  13. Slide 13: Omidubicel manufacturing process

    Omidubicel manufacturing process Omidubicel Infusion Cord Blood Unit (CBU) Selected CBU selected by physician from public cord blood bank Omidubicel NAM - Expanded Cells Stem cells cultured using proprietary NAM technology Non - Cultured Fraction Immune cells, including T cells Scalable manufacturin

  14. Slide 14: Phase 3 global, randomized study design

    Phase 3 global, randomized study • Age 12 - 65 • High - risk hematologic malignancies • Eligible for allogeneic bone marrow transplantation • No matched donor Omidubicel Comparator (standard cord blood) R 14 Primary endpoint: Time to neutrophil engraftment Secondary endpoints: Platelet engraftment,

  15. Slide 15: Phase 3 primary endpoint: reduced time to engraftment

    Phase 3 primary endpoint: Omidubicel significantly reduced time to engraftment 15 INTENT - TO - TREAT MEDIAN TIME TO NEUTROPHIL ENGRAFTMENT (DAYS) 95% CI p - V A LUE Omidubicel (N = 62) 12.0 (10.0, 15.0) p<0.001 Comparator (N = 63) 22.0 (19.0, 25.0) • 125 patients were randomized at 33 sites • Demog

  16. Slide 16: Cumulative incidence of neutrophil engraftment

    Cumulative incidence of neutrophil engraftment Omidubicel (N=52) Comparator (N=56) 16 96% 89% Cumulative Incidence of Neutrophil Engraftment 28 35 42 0 7 14 21 Days post Transplant Per protocol population: received transplantation with omidubicel or comparator per protocol. 1.0 0.8 0.6 0.4 0.2 0.0 M

  17. Slide 17: Omidubicel significantly accelerated platelet recovery

    Randomized Treatment Omi dubi cel UCB Phase 3 secondary endpoint: Omidubicel significantly accelerated platelet recovery PLATELET ENGRAFTMENT AT 42 - DAYS PLATELET ENGRAFTMENT AT 42 - DAYS Omidubicel: 55% Comparator: 28% p = 0.028 Cumulative Incidence of Platelet Engraftment 0 7 14 28 35 42 21 Days

  18. Slide 18: Omidubicel significantly reduced total hospitalization in first 100 days

    Phase 3 secondary endpoint: Omidubicel significantly reduced total hospitalization in first 100 days ALIVE AND OUT OF HOSPITAL IN FIRST 100 - DAYS ALIVE AND OUT OF HOSPITAL IN FIRST 100 - DAYS Omidubicel: Median 60.5 days Compartor: Median 48.0 days p = 0.005 Population: ITT Days Alive and Out of Ho

  19. Slide 19: Omidubicel significantly reduced serious infection rate

    Omidubicel: 37% Randomized Treatment Control: 57% Omidubicel p = 0.027 UCB Phase 3 secondary endpoint: Omidubicel significantly reduced serious infection rate INFECTIONS BETWEEN RANDOMIZATION AND 100 DAYS 1 INFECTIONS BETWEEN RANDOMIZATION AND 100 DAYS 1 1. Proportion (%) of patients with any grade

  20. Slide 20: Omidubicel significantly reduced viral infection rate

    Phase 3 Exploratory Endpoint Omidubicel significantly reduced viral infection rate CUMULATIVE INCIDENCE OF FIRST GRADE 3 VIRAL INFECTION BY 1 YEAR FOLLOWING TRANSPLANTATION (ITT) CUMULATIVE INCIDENCE OF FIRST GRADE 3 VIRAL INFECTION BY 1 YEAR FOLLOWING TRANSPLANTATION (ITT) Randomized Treatment Omid

  21. Slide 21: Exploratory endpoint: Overall survival at 15 months

    Strictly Confidential 0 . 0 0 . 2 0 . 4 1 . 0 0 . 8 0 . 6 0 6 0 1 20 1 8 0 2 4 0 3 0 0 Days Post Randomization 3 60 4 2 0 4 80 Probability of Overall Survival Omidubicel Control Edited for presentation Phase 3 Exploratory Endpoint: Overall Survival at 15 Months (ITT) OVERALL SURVIVAL AT 15 MONTHS AF

  22. Slide 22: Omidubicel Phase 3 key takeaways

    Omidubicel Phase 3 key takeaways Achieved primary endpoint of improved neutrophil engraftment in intent - to - treat analysis Positive randomized, controlled, global Phase 3 registrational trial Achieved all three pre - specified formal secondary end - points Preparing for rolling BLA submission by

  23. Slide 23: Omidubicel Phase 2 Study in Severe Aplastic Anemia

    Omidubicel 23 23 Phase 2 Study in Severe Aplastic Anemia

  24. Slide 24: Omidubicel in severe aplastic anemia

    24 Omidubicel in severe aplastic anemia • Severe aplastic anemia (SAA) is a life - threatening bone marrow failure disorder • 600 - 900 diagnosed with aplastic anemia in US each year 1 • Hematopoietic stem cell transplantation is the only potential for cure in SAA • Omidubicel data from NIH study (D

  25. Slide 25: Omidubicel in aplastic anemia results

    Omidubicel in aplastic anemia • 8 patients engrafted, 1 had graft rejection • 1 patient died due to disseminated adenovirus infection • Neutrophil recovery: median 10 days (range 6 - 14) • Platelet recovery: median 31 days (15 - 40) • 1 patient with acute GVHD ≥grade 2 • No chronic GVHD • Robust imm

  26. Slide 26: Real World Data Collaboration with CIBMTR

    Real World Data 26 Collaboration with the Center for International Blood and Marrow Transplant Research (CIBMTR)

  27. Slide 27: Real world data collaboration with CIBMTR

    Real world data collaboration with CIBMTR 27 Data reported to the Center for International Blood and Marrow Transplant Research (CIBMTR) • Inclusion criteria corresponding to omidubicel Phase 3 trial – Hematologic malignancy – Myeloablative conditioning – Allogeneic HSCT • Donors: – Haploidentical r

  28. Slide 28: Distribution of donor age

    Distribution of donor age Donor age in years, median (range) 28 (18 - 59) 36 (19 - 57) 33 (2 - 74) Donor Matched Unrelated Donor (N=367) Mismatched Unrelated Donor (N=64) Haploidentical Donor (N=229) 28 Count (n) Years

  29. Slide 29: Patient groups

    Patient groups Donors >30 N=326 Donors >30 N=326 Donors ≤ 30 N=334 Donors ≤ 30 N=334 All Patients N=660 29

  30. Slide 30: Overall survival is associated with donor age

    Overall survival is associated with donor age (N=334) (N=326) 30

  31. Slide 31: Overall survival by donor age: multivariable analysis

    Overall survival by donor age — multivariable analysis: 17% excess risk for every additional decade of donor age Overall Survival: Age as a Continuous Variable Donor age 1.17 0.038 Donor MUD r eference MMUD 1.20 0.523 Haplo 0.89 0.546 Patient age 1.12 0.103 Disease AML r eference ALL 1.00 0.99 MDS 1

  32. Slide 32: Real world data collaboration

    Real world data collaboration Cord blood, the starting material for omidubicel, is considered the most naïve graft source Donor age is an important conside r ation for donor selection Additional data encompassing 2019 transplants will be analyzed when available Advances in the development of graft s

  33. Slide 33: Omidubicel Commercial Potential and Launch Readiness

    Omidubicel 33 Commercial Potential and Launch Readiness Michele Korfin Chief Operating and Chief Commercial Officer

  34. Slide 34: Substantial market opportunity for omidubicel

    34 Substantial market opportunity to both improve known issues with existing donor source as well as expand the market to treat untransplanted patients Omidubicel opportunity Increase Access Improve Outcomes Patient s Challenges ~13,000 patients with hematologic malignancies are eligible for transpl

  35. Slide 35: Omidubicel vs current transplants on different metrics

    Source: Trinity Market Research (based on target product profile before the Phase 3 study was completed 35 *Attributes not shown for current transplants. Median time to neutrophil recovery CD34+ Cell Dose Duration of hospital stay Median time to platelet recovery Neutrophil engraftment at day 42 Non

  36. Slide 36: Advantages resonate with payers

    36 Advantages also resonate with payers as omidubicel presents a clear value proposition PERCEIVED ADVANTAGES OF OMIDUBICEL PERCEIVED ADVANTAGES OF OMIDUBICEL • Faster engraftment / better neutrophil recovery – Payers note speed of engraftment as a key advantage of omidubicel vs. the cord blood comp

  37. Slide 37: Omidubicel advantages over existing donor sources

    37 Omidubicel presents several advantages over existing donor sources and is anticipated to capture 18% of current volumes at peak levels of adoption ( time to peak ~ 3 years) vs. UCB: • Better efficacy (neutrophil engraftment time, average days in the hospital, and neutrophil recovery) • Eliminates

  38. Slide 38: Increased access through improved eligibility and transplantation rates

    38 Omidubicel is also anticipated to increase access for the number of transplanted patients through improved eligibility and transplantation rates Eligible Patients Allo HCT eligible patients Transplanted Patients Eligible patients receiving transplant Transplant Candidates Patients arriving at tra

  39. Slide 39: Omidubicel launch goals

    39 Omidubicel will be a therapy option for HSCT patients who do not have access to a matched related donor* Omidubicel Launch Goals Rapid time to peak market share: ~ 3 years to reach peak ~ 2,000 patients treated with Omidubicel per year, upon reaching peak (supported by market research) Positive p

  40. Slide 40: Key commercial activities and infrastructure build-out

    Key commercial activities and infrastructure build - out are underway to prepare for a successful omidubicel U.S. launch Key Focus: Positive Patient Experience Educating transplant centers 1 Ensuring commercial manufacturing readiness 4 3 Building patient and hospital support services 2 Working with

  41. Slide 41: Education of U.S. transplant centers

    Gamida Cell has initiated the plan for education of the U.S. transplant centers Approximately 70 transplant centers account for ~80% of bone marrow transplants in U.S. Top treating site Top treating & omidubicel trial site Field Force Team Industry Surrogates Medical Science Liaisons 10 – 15 FTEs Ac

  42. Slide 42: Commercial payers insure the majority of transplant patients

    42 Commercial payers are estimated to insure the majority of the transplant patients — feedback indicates commercial payers would reimburse omidubicel via carve - out Commercial, 56.0% Medicare, 24.6% Medicaid, 11.3% Uninsured, 8.1% Analysis by Insurance Type 1 N = 5,914 . 1. State Health Access Dat

  43. Slide 43: Preparing for potential reimbursement approaches

    43 Gamida will be prepared for potential reimbursement approaches • Published data supports that ~100% of U.S. payers anticipate covering one - time therapies, with curative intent • Gamida has a good understanding of the Reimbursement approach that payers will take upon omidubicel FDA approval • Ma

  44. Slide 44: Payer coverage and reimbursement approaches for CAR-T therapies

    44 Source: Public data on therapy pricing Payers have developed coverage and reimbursement approaches for CAR - T therapies $373,000 $373,000 $373,000 $475,000 U.S. List Prices U.S. List Prices (DLBCL) ( A LL) • CAR - T Therapies initially launched in 2017 in the U.S. • Pricing ranged from $373K - $

  45. Slide 45: Hospitalization is the biggest cost driver of HSCT

    45 Omidubicel has demonstrated a significant reduction in hospitalization time, the biggest cost driver of HSCT ALLOGENEIC STEM CELL TRANSPLANTS CHARGES ALLOGENEIC STEM CELL TRANSPLANTS CHARGES $319,300 $27,700 $537,900 $81,600 $71,300 $33,900 $ 2 0 0 , 0 00 $0 $400,000 $600,000 $800,000 $1,000,000

  46. Slide 46: Introduction to Gamida Cell Assist

    Introduction to Gamida Cell Assist We are building a patient support operation to provide the assistance and services to healthcare professionals, patients, and caregivers that will support access to our therapy and strive to ensure a positive personalized experience 3 46

  47. Slide 47: Gamida Cell Assist key aspect of patient-centric launch

    Gamida Cell Assist will be a key aspect of our patient - centric launch T ransplant Center Manufacturing Cord Blood Bank • We are a support and solutions - oriented team that will provide a personalized, high touch experience • Gamida Cell Assist will provide a single point of contact for patients a

  48. Slide 48: Gamida Cell Assist: resource for transplant center and patient

    Gamida Cell Assist: resource for the transplant center and patient from the point of omidubicel treatment decision HCP Identifies Patient Gamida Services (CBU selection, ordering, distribution, supply chain.) Manufacturing Omidubicel Delivered Infusion Post Infusion Benefit Verification/Appeals Trav

  49. Slide 49: Manufacturing readiness on track to support potential 2H21 launch

    49 Manufacturing readiness on track to support potential 2H21 launch Photo of Gamida Cell - owned facility. Dual sourcing for manufacturing established for commercialization of omidubicel: Kiryat Gat (Israel) • Gamida Cell owned facility • Construction completed in 2020 and hiring complete for initi

  50. Slide 50: Current commercialization focus is the U.S. market

    50 Source: European Society for Blood and Marrow Transplantation Activity Survey 2018 *Transplant data consists of all ages Current commercialization focus is the U.S. Market — global evaluation in process ~15,000 patients with hematologic malignancies are eligible for transplant annually in the EU

  51. Slide 51: Commercial potential and launch readiness key takeaways

    51 Commercial potential and launch readiness key takeaways This is one patient and results may not be indicative. Omidubicel is investigational and safety and efficacy have not been established by any agency • Potential to be first FDA - approved cell therapy for bone marrow transplantation • Compel

  52. Slide 52: GDA-201: Harnessing Innate Immunity Using NK Cells to Treat Cancer

    GDA - 201 52 Harnessing Innate Immunity Using Natural Killer (NK) Cells to Treat Cancer Tracey Lodie, Ph.D. Chief Scientific Officer

  53. Slide 53: Putting NK cells to work using our NAM technology platform

    Putting NK cells to work using our NAM technology platform Benefits of NK Cells • Natural killer (NK) cells infusion is a promising immune therapy for cancer – No HLA matching required – Synergy with antibodies – Potential for off - the - shelf therapy • Expansion is necessary to obtain clinically m

  54. Slide 54: Phase 1 Trial of GDA-201 in Refractory NHL and Multiple Myeloma

    GDA - 201 54 Phase 1 Trial of GDA - 201 in Patients with Refractory Non - Hodgkin Lymphoma and Multiple Myeloma Ronit Simantov, M.D. Chief Medical Officer

  55. Slide 55: Phase 1 study of GDA-201 in NHL and multiple myeloma

    Phase 1 study of GDA - 201 in patients with non - Hodgkin lymphoma and multiple myeloma Patients with Non - Hodgkin lymphoma (NHL) or multiple myeloma (MM) (n=35) Fludarabine/cyclophosphamide Lymphodepleting preparative regimen GDA - 201 Rituxan ® (NHL) or Empliciti ® (MM) • Primary endpoint: Maximu

  56. Slide 56: Adverse events severity

    G ( rade 3 - 5 Adverse Events Severity N=35) Event Grade 3 Grade 4 Grade 5 Total Hematologic 9 19 0 28 Anemia 3 3 • Adverse events mostly attributed to lymphodepleting chemotherapy • Most common adverse events were decreased neutrophil count, febrile neutropenia, anemia and low platelet counts • No

  57. Slide 57: Response rates

    Response rates 57 19 PATIENTS WITH NHL 13 CR 1 PR 5 PD ORR: 74% CR rate: 68% Follicular Lymphoma (FL) (n=11) Diffuse Large B - Cell Lymphoma (DLBCL) (n=8) 8 CR 5 CR 1 PR

  58. Slide 58: GDA-201 is highly active in non-Hodgkin lymphoma

    58 4 5 9 23 26 27 19 30 33 29 2 31 36 37 1 3 24 28 35 PT# DIAGNOSIS 004 FL 005 FL 009 DLBCL 023 FL 026 DLBCL 027 DLBCL 019 DLBCL 030 FL 033 DLBCL 029 FL 002 FL 036 FL 031 FL 037 FL 001 DLBCL 003 DLBCL 024 MCL 028 DLBCL 035 FL Months 0 2 4 6 8 10 12 14 16 18 20 22 24 26 28 Complete Response Partial R

  59. Slide 59: Patient 009 case

    Pt 009: 6 - month post GDA - 201 Pt 009: Baseline 59 Patient 009 • 57 - year - old man with history of CLL and Richter’s transformation - large cell lymphoma, measurable retroperitoneal lymph nodes at baseline • Prior therapy: FCR - light, Rituximab/Bendamustine Ibrutinib/Revlimid, R - CHOP, Venetoc

  60. Slide 60: OS and PFS following GDA-201

    OS and PFS following GDA - 201 ++ + + + + + + ++ + 0.00 0.25 0.50 0.75 1.00 0 3 6 Months 9 1 2 Survival probability % 1 year Overall Survival + ++ + + + +++ 0.00 60 0.25 0.50 0.75 1.00 0 3 6 Months 9 1 2 Survival probability % 1 year Progression - free Survival Median follow - up is 10 months (range

  61. Slide 61: GDA-201 study conclusions

    Phase 1 GDA - 201 study: conclusions 61 • GDA - 201 is a novel cell product manufactured with nicotinamide without genetic engineering • GDA - 201 target dose of 2 x 10 8 cells/kg in multi - dose infusions is safe and well tolerated • GDA - 201 cells expand in blood, traffic to bone marrow and lymph

  62. Slide 62: Meet Wayne

    Meet Wayne 62 Wayne participated in the Phase 1/2 clinical study of GDA - 201 at the University of Minnesota to treat lymphoma. His lymphoma is in remission a year after treatment. “[The doctors] were finding that the lymphoma appeared to have evaporated, completely gone away, that the lymph nodes w

  63. Slide 63: Pipeline Deep Dive Summary

    Pipeline Deep Dive Summary 63 Julian Adams, Ph.D. CEO

  64. Slide 64: We are inspired to cure

    We are inspired to cure Potential to expand any cell type, including stem cells and NK cells Preparing for BLA submission and potential launch Promising early clinical activity in heavily pre - treated patients with lymphoma Preparing for multi - center Phase 1/2 study Potential to launch first - ev

  65. Slide 65: A Patient's Perspective

    A Patient’s Perspective gamida (ell

  66. Slide 66: Q&A

    Q&A gamida (ell

Gamida Cell — Investor Day (December 2020) on 6ix